However, the duration of the effect of NS4591 as facilitator of erectile function seems limited, therefore further studies should be conducted to elucidate whether a drug, which is more selective for the KCa2.3 channels, and with longer duration of action could provide a novel approach for treatment of erectile dysfunction. This evidence concerns the gene KCNN3 and erectile dysfunction.